VivoSeq
Other

Factor Xa Inhibitor

0

Pipeline Programs↗

2

Active Trials↗

5

Companies Involved↗

Factor Xa Inhibitor is an early-stage landscape with 0 programs across 5 companies. The most active players are Portola Pharmaceuticals, Astellas, Takeda.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Portola Pharmaceuticals

0 programs

PreclinicalAstellas logo

Astellas

0 programs

PreclinicalTakeda logo

Takeda

0 programs

PreclinicalCSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

0 programs

PreclinicalBayer logo

Bayer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

8

clinical trials

Completed5 · 63%
Recruiting1 · 13%
Unknown status1 · 13%
Active, not recruiting1 · 13%

Clinical Trials

Trial Activity

8 trials

A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
Recruiting·Takeda logoTakeda·Phase 3·NCT05156983·328 enrolled
Perioperative Management of Factor Xa Inhibitors
Active, not recruiting·SSeoul National University Hospital·N/A·NCT05801068·2,500 enrolled
Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)
Completed·Astellas logoAstellas·Phase 2·NCT00353678·1,141 enrolled
Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis
Completed·Bayer logoBayer·Phase 2·NCT00395772·543 enrolled
Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)
Completed·PPortola Pharmaceuticals·Phase 2·NCT00375609·215 enrolled
Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin
Completed·PPortola Pharmaceuticals·Phase 2·NCT00742859·508 enrolled
The Effect of Contrast Agents on the Anticoagulant Properties of Oral Factor Xa Inhibitors
Completed·—·N/A·NCT04611386·65 enrolled
Phase I Study of Direct Coagulation Factor Xa Inhibitor SYHA136 Tablets in Chinese Healthy Volunteers
Unknown status·CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logoCSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT04036656·56 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)